Compare · DXCM vs HTFL
DXCM vs HTFL
Side-by-side comparison of DexCom Inc. (DXCM) and Heartflow Inc. (HTFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and HTFL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.34B, about 11.1x HTFL ($2.55B).
- Over the past year, DXCM is down 15.4% and HTFL is down 1.2% - HTFL leads by 14.2 points.
- DXCM has been more active in the news (30 items in the past 4 weeks vs 8 for HTFL).
- DXCM has more recent analyst coverage (25 ratings vs 7 for HTFL).
- Company
- DexCom Inc.
- Heartflow Inc.
- Price
- $73.42-1.94%
- $29.54-4.49%
- Market cap
- $28.34B
- $2.55B
- 1M return
- +19.70%
- +2.91%
- 1Y return
- -15.42%
- -1.20%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2025
- News (4w)
- 30
- 8
- Recent ratings
- 25
- 7
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)
Latest HTFL
- Chief Medical Officer Rogers Campbell exercised 9,219 shares at a strike of $19.00 and sold $261,266 worth of shares (9,219 units at $28.34) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Heartflow Inc.
- SEC Form 10-Q filed by Heartflow Inc.
- Heartflow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
- Chief Executive Officer Farquhar John C.M. sold $657,005 worth of shares (22,562 units at $29.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 519,397 units (SEC Form 4)
- A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
- The Future of Intoxication Detection May Be in Your Voice
- Chief Accounting Officer Jones Marie L. covered exercise/tax liability with 567 units of Common Stock., decreasing direct ownership by 2% to 31,083 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Rogers Campbell covered exercise/tax liability with 2,271 shares, decreasing direct ownership by 3% to 78,731 units (SEC Form 4) (withholding obligation)